Plain-English translation of NCT07365423 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an affordable antifungal drug that has been used safely for decades to treat skin and nail infections, to see if it might also help slow prostate cancer that has come back after surgery or radiation. Researchers believe the medication may work against cancer cells in a similar way it fights fungus. This is an early-stage test to find the right dose and see if the treatment is effective and safe for men with recurring prostate cancer.
Many men with prostate cancer develop recurrence after initial treatment, but at a stage where the cancer is not yet visible on standard scans. The standard treatments currently available have significant side effects like hot flashes, bone loss, and sexual dysfunction, and many patients want to delay or avoid starting these therapies. This trial explores whether the medication might offer a gentler alternative to buy time before starting more intensive treatments.
You likely qualify if…
You likely don't qualify if…
The trial has two stages: first, a small group of 27 patients will test three different doses of the medication to find the safest and most promising dose; then additional patients will be enrolled to further study that selected dose. You would take the medication by mouth daily for up to 12 cycles, with each cycle lasting 28 days (about one year total). You will have regular clinic visits and blood tests to check how you are doing and whether your PSA levels are changing.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Switzerland